ArticleMolecular biology reports2025
Association of PD-1 immune checkpoint polymorphisms with oral cancer risk: results from a Pakistani case-control study.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOral Cancer (OC) is a major public health concern in Pakistan, ranking as the leading cause of cancer-related mortality in males and a significant contributor in females. Genetic variations, predominantly single nucleotide polymorphisms (SNPs) in immune checkpoint genes, are implicated in OC susceptibility. However, their role remains unclear. This study investigates PD-1 gene polymorphisms and their association with OC risk in the Pakistani population. METHODOLOGY: A case-control study was conducted from 2019 to 2022, recruiting 215 OC cases and 411 healthy controls for genetic analysis. High-Resolution Melting (HRM) analysis and Sanger sequencing were used for genotyping rs36084323 and rs2227981, while ELISA was performed to evaluate PD-1 protein expression levels.
resultsGenotypic analysis revealed a significant association between rs36084323 and OC susceptibility (p = 0.02; OR = 1.99; 95% CI = 1.09-3.61), particularly in individuals carrying the CC and CT genotypes. However, rs2227981 showed no significant association. Haplotype analysis indicated that the CG haplotype (p = 0.004; OR = 1.68; 95% CI = 1.18-2.39) was significantly associated with higher OC risk, while the AG haplotype (p = 0.02; OR = 0.52; 95% CI = 0.29-0.94) was linked to a protective effect. PD-1 protein expression levels did not differ between cases and controls.
conclusionThe PD-1 rs36084323 polymorphism may serve as a genetic biomarker for OC susceptibility in Pakistan, emphasizing the need for targeted genetic screening and early detection strategies. Further research could uncover novel biomarkers and therapeutic targets for OC in the Pakistani population.
Indexed as
Identifiers
40960692What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.